NEMUS Bioscience, Inc. (OTCBB: NMUS) is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids. NEMUS Bioscience Inc. is developing a proprietary class of product candidates that are designed to target the body's nervous and immune systems without inducing many of the undesirable side effects. SNNLive spoke with John Hollister, CEO of Nemus Bioscience, Inc. at the Healthcare Media Day 2015 in San Francisco, CA.
Mr. Hollister begins the interview with an overview of the company, “Nemus Bioscience is a drug development company. We’re based in Southern California, and we’re very unique in that we are a cannabis-derived pharmaceutical company. We have a unique license with the University of Mississippi, the only entity in the US that’s actually licensed to cultivate cannabis, and we’re using their experience from 1968 and turning that into pharmaceutical products.”
Headquartered in Costa Mesa, Mr. Hollister explains that the company has, “licensed an active compound from the University of Mississippi, we’re their sole partners, and that compound is a THC prodrug – that is, that drug is able to be absorbed into the human body in a variety of different ways that the parent compound cannot, and our lead compound is targeted for treatment of glaucoma; an eye-drop for glaucoma.” For more information about Nemus Bioscience, Inc., please visit: www.NEMUSBioscience.com
© 2017 Stock News Now
Supported by Superior Web Solutions